Abstract: The present technology is directed to compounds that inhibit of the interaction of RNA-binding proteins with RNA, intermediates thereof, compositions thereof, and methods of treatment utilizing such compounds, where the compounds are of Formula (I).

Abstract: Methods for treating IBD or an IBD related disorder in a subject in need thereof are provided that comprise combined intrathecal administration of a polynucleotide comprising a CLN1 open reading frame and intravenous administration of the polynucleotide. The polynucleotide comprising the CLN1 open reading frame is a wild-type CLN1 polynucleotide. In another aspect, the polynucleotide comprising the CLN1 open reading frame comprises codon-optimized polynucleotide sequence of the polynucleotide or its complement and is codon-optimized for expression in a human cell.

Abstract: A method for performing retrospective magnetic resonance imaging (MRI) artifact correction includes receiving, as input, an MRI image having at least one artifact; using a trained adversarial network for performing retrospective artifact correction on the MRI image, wherein the trained adversarial network is trained using unpaired artifact-free MRI images and artifact-containing MRI images; and outputting, by the trained adversarial network, a derivative MRI image related to the input, wherein the at least one artifact is corrected in the derivative MRI image.

Abstract: Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.

Abstract: A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

Abstract: Provided are methods for identifying pancreatic cancer subtypes in a subject and treating the same. In some embodiments, the method comprise obtaining gene expression levels for each of the following genes in the biological sample: GPR87, KRT6A, BCAR3, PTGES, 1TGA3, C16orf74, S100A2, KRT5, REG4, ANXA10, GATA6, CLDN18, LGALS4, DDC, SLC40A1, CLRN3; performing pair-wise comparisons of gene expression levels for combinations of these genes, and calculating a Raw Score for the biological sample, wherein the Raw Score is indicative of the pancreatic cancer subtype in the subject. Also provided are methods for identifying differential treatment strategies for subjects diagnosed with PDAC, methods for treating PDAC patients based on the subtype of PD AC the patients have; and methods for classifying subjects diagnosed with PDAC as having a basal-like subtype or a classical subtype of PDAC.

Abstract: A microfluidic device includes a plurality of reaction wells; and a plurality of solid supports, and each of the solid supports has a reagent attached thereto. The reagent is attached to the solid support via a labile reagent/support bond such that the reagent is configured to be cleaved from the support via a cleaving operation.

Abstract: Systems and methods for simulating the insertion of a device via cannulation include an external shell which is at least partially filled with a silicone material, a simulated venous flow path, a simulated arterial flow path, one or more pumps to provide fluid to these flow paths, and a visible atrium in fluid communication with the venous flow path. The venous and arterial flow paths are made of flexible and distensible tubing, which is at least partially embedded within the silicone material in cannulation regions, and which is configured to be pierced to allow for insertion of a device therein. The atrium comprises a translucent front wall to enable, before, during, or after insertion of the device, visible inspection inside of the atrium.

Abstract: Provided are methods for de novo deconvoluting of datasets with multiple samples and/or estimating compartment weights for single samples. In some embodiments, the methods include applying the process or processes to a dataset with multiple samples or to a single sample, whereby the dataset is deconvoluted and/or a compartment weight is estimated. In some embodiments, the dataset relates to RNA sequence and/or gene expression data, optionally tumor RNA sequence and/or gene expression data, wherein the tumor is in some embodiments a pancreatic tumor, a prostate cancer, a bladder cancer, or a breast cancer.

Abstract: Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

Abstract: Face mask devices, systems, and methods of use include a frame that holds a suitable filter material, including a face mask, over the user's face to form a seal and prevent unfiltered air from being inhaled through the nose or mouth of the user without first passing through the filter material. The frame is removably attached over the users face by, for example, adjustable straps. The frame may be adjustable in size to be suitable for use on user's having different facial sizes, shapes, and/or geometries.

Abstract: Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.

Abstract: Methods for generating a prognostic and/or subtype signature for a subject with pancreatic ductal adenocarcinoma (PDAC) are provided. In some embodiments, the methods include determining expression levels for one or more genes listed in Tables 2-5, 9, 10, or 11, and/or the DE-S and/or DE-T subset of genes in PDAC cells obtained from the subject, wherein the determining provides a prognostic and/or subtype signature for the subject. Also provided are methods for classifying a subject diagnosed with pancreatic ductal adenocarcinoma (PDAC) as having an activated stroma subtype or a normal stroma subtype of PDAC and/or a basal subtype or a classical subtype of PDAC; and methods for identifying a differential treatment strategy for a subject diagnosed with pancreatic ductal adenocarcinoma (PDAC).

Abstract: Methods for imaging a sample using fluorescence microscopy, systems for imaging a sample using fluorescence microscopy, and illumination systems for fluorescence microscopes. In some examples, a method includes positioning the sample such that a plane of interest of the sample is coplanar with a focal plane of a detection objective of a microscope. The method includes positioning a paraboloidal mirror around the sample such that a focal point of the paraboloidal mirror is coplanar with the focal plane of the detection objective and the plane of interest of the sample. The method includes directing a beam of annularly collimated excitation light on the paraboloidal mirror to focus a disc of light on the sample and thereby to provide 360 degree lateral illumination of the sample. The method includes imaging the sample through the detection objective.

Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Abstract: The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyimide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

Abstract: Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects are provided. In one aspect, the apparatus can include a platform on which a subject is positionable and at least one motion stage for controlling a spatial position of at least one ultrasound transducer relative to the platform in order to acquire ultrasound image data of the subject. Methods for preclinical ultrasound raster scanning of at least one organ or tissue in a subject are also provided, where the at least one organ or tissue is a heart.

Abstract: Devices and methods generate an ordered restriction map of genomic DNA extracted from whole cells, nuclei, whole chromosomes, or other sources of long DNA molecules. The devices have a fluidic microchannel that merges into a reaction nanochannel that merges into a detection nanochannel at an interface where the nanochannel diameter decreases in size by between 50% to 99%. Intact molecules of DNA are transported to the reaction nanochannel and then fragmented in the reaction nanochannel using restriction endonuclease enzymes. The reaction nanochannel is sized and configured so that the fragments stay in an original order until they are injected into the detection nanochannel. Signal at one or more locations along the detection nanochannel is detected to map fragments in the order they occur along a long DNA molecule.

Abstract: This present disclosure provides devices, systems, and methods relating to the management of a subject's medical needs involving safely accessing a body cavity. In particular, the present disclosure is directed to body cavity conduit devices and systems that facilitate repeated access to a subject's body cavity for removing fluid or performing a procedure in a manner that provides enhanced comfort, safety, and efficacy.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.